Tariquidar
From Wikipedia, the free encyclopedia
 |
|
|
Tariquidar
|
|
| Systematic (IUPAC) name | |
| N-[2-[[4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C38H38N4O6 |
| Mol. mass | 646.73 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Tariquidar (INN/USAN) is an P-glycoprotein inhibitor[1] undergoing research for the treatment of cancer.
[edit] References
- ^ Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 2008;3:1302-12. PMID 18234154.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
